SARS-CoV-2 vaccination, ABO blood group and risk of COVID-19: population-based cohort study.

ABSTRACT:

Objective

To compare outcomes between O and non-O blood groups, and by modified RNA (mRNA) and adenovirus-vectored (Ad-V) vaccines.

Design

Population-based cohort study.

Setting

All of Ontario, Canada. Linked data sets captured clinical encounters, vaccinations and laboratory testing for SARS-CoV-2.

Participants

Individuals aged 12+ years with known ABO blood group and free of SARS-CoV-2 before 15 January 2021.

Main outcomes measures

The main exposure, first SARS-CoV-2 vaccination, was modelled in a time-varying manner. O and non-O blood group was known prior to vaccination. SARS-CoV-2 infection, and severe COVID-19 (hospitalisation or death), were assessed starting 14 days after vaccination, up to 27 June 2021.

Results

2 472 261 individuals were

SUBMITTER: Ray JG 

PROVIDER: S-EPMC9297000 | biostudies-literature | 2022 Jul

REPOSITORIES: biostudies-literature